



Press release from Emotra AB (publ)

Göteborg, October 16, 2020

## **CEO Daniel Poté intends to exercise his subscription warrants**

**Daniel Poté, Emotra AB's CEO ("Emotra" or "the Company") has notified that he intends to exercise his right to convert 50% of his subscription warrants in connection with the second phase of Emotra's rights issue.**

**Daniel Poté, CEO of Emotra says:**

*"I will subscribe for more shares in Emotra as I believe in the goals we have set up for the Company and as our activities are based on the right competences. Seeing that EDOR has a great potential as a future method, we will continue to cooperate with researchers and technology and business developers."*

As notified on October 6, 2020, the exercise price for the subscription warrants has been set to 0.40 SEK per share. One (1) subscription warrant gives the owner the right to subscribe for one (1) new share in Emotra in the period October 9 to 23 inclusive, 2020.

**For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail:

[daniel@emotra.se](mailto:daniel@emotra.se)

**Fel! Hittar inte referensälla.**

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)